Katherine G Tarlock, MD

"I am dedicated to advancing our understanding of leukemia and being able to offer every child and family the best care available. I love being involved in clinical and translational research as I believe that improved understanding the biology of cancers is essential to developing new and better therapies for patients and will result in more children and young adults being cured. The privilege of caring for patients and families during challenging medical diagnoses is one of the aspects that drew me to the field of pediatric hematology/oncology and continues to be one of the best parts of my job."
  • Biography

    Dr. Tarlock is a clinician at Seattle Children’s Hospital, an Assistant Professor of Pediatrics at the University of Washington School of Medicine and holds a Research Affiliate at the Fred Hutchinson Cancer Center. Dr. Tarlock is an active member of Myeloid Disease Committee of the Children’s Oncology Group (COG). She is also an active member of the New Agents Committee. She was the chair of one COG trial for children with relapsed/refractory AML and has another trial in development. Dr. Tarlock is active in research efforts in acute myeloid leukemia (AML), with a focus on development of novel therapies. She is also active in efforts for pediatric global oncology including serving on the Plenum Committee of the Children’s International Consortium on Acute Leukemia, Vice-Chair for Health Volunteers Overseas, and serves as an associate faculty member at the Uganda Cancer Institute in Kampala, Uganda.

    Board Certification(s)

    Pediatric Hematology-Oncology


    Rosalind Franklin University of Medicine/Science, North Chicago, IL


    Stanford University School of Medicine, Stanford, CA


    Seattle Children's Hospital, Seattle, WA

    Clinical Interests

    Pediatric leukemias and lymphomas, high risk leukemias, targeted therapies, global health in Pediatric hematology/oncology

    Research Description

    My research is focused on the identification of genomic lesions in children with acute myeloid leukemia (AML) that affects how they respond to current therapies. In addition, I am focused on the identification novel therapeutic targets and novel therapies, including immunotherapies, for children for whom current therapies are inadequate.  I am actively engaged in the development of early phase clinical trials to evaluate targeted therapies in children with AML. I also believe that children all over the world should have equal opportunity to the best care. I am actively engaged in several research efforts in improving care for children with leukemia in resource limited settings. This research includes the development of a protocol for children with acute lymphoblastic leukemia (ALL) for use in low- and middle-income countries as well as research to understand the biology of children and adults with ALL and AML in sub Saharan Africa.

  • Patient Testimonials

    • {{ testimonial.displayName }}
      {{ testimonial.location }}
      {{ formatTestimonialDate(testimonial.date) }}

      {{ testimonial.testimony }}

  • Awards and Honors

    Award Name Award Description Awarded By Award Date
    {{ award.name }} {{ award.description }} {{ award.organization }} {{ award.displayDate }}
  • Publications

  • Presentations

    Presentation Title Event Location Date
    {{ presentation.title }} {{ presentation.presentedAt }} {{ presentation.location }} {{ presentation.displayDate }}
  • Research Funding

    Grant Title Grantor Amount Award Date
    {{ funding.title }} {{ funding.grantedBy }} {{ funding.amount }} {{ funding.displayDate }}
  • Clinical Trials and Research Studies

    {{ item.t }}

    {{ item.st }}

    {{ item.obj }}

    Condition: {{ item.con }} Phase: {{ item.ph }} Clinicaltrials.gov ID: {{ item.nct }}

    No clinical trials found for Katherine G Tarlock, MD.